When patents create an unbalanced system of protection, regulatory exclusivities, which safeguard a firm’s data from being copied by competitors while still allowing scientific collaboration, offer a better alternative.
The best way for Canada to contribute to the development of new antibiotics is for the government to play a major role in aligning firms and universities, and to fund research.
